Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments EP News Bureau Mar 18, 2022 Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective 1st…
Biogen applies for approval of Alzheimer’s drug, aducanumab in Japan Reuters Dec 10, 2020 Biogen and Eisai have jointly developed three experimental drugs for Alzheimer’s
